2. Search Result
Search Result
Isoforms Recommended: αIIbβ3
Results for "

GPIIbIIIa

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

3

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10304A
    Orbofiban acetate

    		Integrin Cardiovascular Disease
    Orbofiban acetate is an orally active platelet GPIIb/IIIa antagonist that inhibits platelet aggregation.
    Orbofiban acetate
  • HY-P0074
    GPRP
    1 Publications Verification

    Gly-Pro-Arg-Pro; Pefa 6003

    		 Integrin Cardiovascular Disease
    GPRP (Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction of fibrinogen with the platelet membrane glycoprotein IIb/IIIa complex (GPIIb/IIIa) .
    GPRP
  • HY-P0074A
    GPRP acetate
    1 Publications Verification

    Gly-Pro-Arg-Pro acetate; Pefa 6003 acetate

    		 Integrin Cardiovascular Disease
    GPRP acetate (Gly-Pro-Arg-Pro acetate) is a fibrin polymerization inhibitor that inhibits the interaction of fibrinogen with the platelet membrane glycoprotein IIb/IIIa complex (GPIIb/IIIa) .
    GPRP acetate
  • HY-119158
    VU0652925

    		Protease Activated Receptor (PAR) P-selectin Inflammation/Immunology
    VU0652925, an analog of BMS986120, is a PAR4 antagonist, with IC50 values of 43 pM and 39.2 pM for PAC1 and P-selectin, respectively. VU0652925 is able to suppress GPIIbIIIa activation .
    VU0652925
  • HY-10304
    Orbofiban

    		Integrin Cardiovascular Disease
    Orbofiban is an orally active platelet GPIIb/IIIa antagonist that inhibits platelet aggregation.
    Orbofiban
  • HY-10314
    Lotrafiban

    SB-214857

    		 Integrin Cardiovascular Disease
    Lotrafiban is an orally-active platelet GPIIb/IIIa blocker for research of coronary and cerebrovascular disease.
    Lotrafiban
  • HY-10314A
    Lotrafiban hydrochloride

    SB-214857-A

    		 Integrin Cardiovascular Disease
    Lotrafiban hydrochloride is an orally-active platelet GPIIb/IIIa blocker for research of coronary and cerebrovascular disease.
    Lotrafiban hydrochloride
  • HY-107590
    GR144053 trihydrochloride

    		Integrin Cardiovascular Disease
    GR 144053 trihydrochloride is a selective and non-peptic GPIIb/IIIa inhibitor (IC50=37 nM) .
    GR144053 trihydrochloride
  • HY-P3523
    KGDS

    		Integrin Others
    KGDS is synthetic peptides, targeting integrin GPIIb-IIIa located on the membrane of human activated platelets. Amino acid sequence: Lys-Gly-Asp-Ser .
    KGDS
  • HY-10306
    Gantofiban

    		Integrin Cardiovascular Disease
    Gantofiban is a GPIIb/IIIa integrin receptor antagonist. By binding to this receptor, Gantofiban can effectively inhibit platelet aggregation, thereby exerting its antithrombotic effect .
    Gantofiban
  • HY-122230
    UR-3216

    		Integrin Cardiovascular Disease
    UR-3216 is a selective, and orally active platelet surface glycoprotein (GPIIb/IIIa) receptor antagonist. UR-3216 has the potential for cardiovascular diseases research .
    UR-3216
  • HY-167848
    DMP-728 free base

    XL-118

    		 Others Cardiovascular Disease
    DMP-728 free base (XL-118) is a highly potent and selective GPIIb/IIIa antagonist with antiplatelet and antithrombotic activities. DMP-728 free base can inhibit ADP-induced human platelet aggregation in vitro, with an IC50 of 46 nmol/L, and can significantly reduce the interaction between fibrinogen and human platelets or Binding of purified human GPIIb/IIIa receptors. DMP-728 free base exhibits dose-dependent antiplatelet effects in anesthetized mongrel dogs, effectively inhibiting ADP-induced platelet aggregation and prolonging template bleeding time .
    DMP-728 free base
  • HY-10315
    Elarofiban

    RWJ-53308

    		 Integrin Cardiovascular Disease
    Elarofiban (RWJ-53308) is a nonpeptide, orally active antagonist for fibrinogen receptor αIIbβ3 (GPIIb/IIIa), with an IC50 of 0.15 nM. Elarofiban has the potential for platelet mediated thrombotic disorders research .
    Elarofiban
  • HY-120080
    UR-2922

    		Others Others
    UR-2922 is a platelet GPIIb/IIIa antagonist with antiplatelet aggregation and cardiovascular disease inhibition activities. UR-2922 has high affinity for human platelet receptors and has good pharmacokinetic properties, and can be used to inhibit cardiovascular diseases.
    UR-2922
  • HY-107867
    (±)-Clopidogrel bisulfate

    		Others Cardiovascular Disease
    Clopidogrel sulfate is an antiplatelet agent. Specifically, Clopidogrel sulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. Clopidogrel sulfate can be used for research of heart disease and stroke .
    (±)-Clopidogrel bisulfate
  • HY-10315A
    Elarofiban diTFA

    		Integrin Cardiovascular Disease
    Elarofiban diTFA is the salt form of Elarofiban (HY-10315) with two TFA. Elarofiban diTFA is a nonpeptide, orally active antagonist for fibrinogen receptor αIIbβ3 (GPIIb/IIIa), with an IC50 of 0.15 nM. Elarofiban diTFA has the potential for platelet mediated thrombotic disorders research .
    Elarofiban diTFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: